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Abstract
The mainstay of hemodynamic treatment of septic shock is fluid resuscitation followed by vasopressors where fluids
alone are insufficient to achieve target blood pressure. Norepinephrine, a catecholamine, is the first-line vasopressor
used worldwide but given that all routinely used catecholamines target the same adrenergic receptors, many
clinicians may add a non-catecholamine vasopressor where refractory hypotension due to septic shock is present.
However, the timing of this additional intervention is variable. This decision is based on three key factors:
availability, familiarity, and safety profile. In our opinion, further consideration should be potential vasopressor
response because following appropriate volume resuscitation, the response to different vasopressor classes is
neither uniform nor predictable. Critically ill patients who are non-responders to high-dose catecholamines have a
dismal outcome. Similarly, patients have a variable response to non-catecholamine agents including vasopressin
and angiotensin II: but where patients exhibit a blood pressure response the outcomes are improved over non-
responders. This variable responsiveness to vasopressors is similar to the clinical approach of anti-microbial
sensitivity. In this commentary, the authors propose the concept of “broad spectrum vasopressors” wherein patients
with septic shock are started on multiple vasopressors with a different mechanism of action simultaneously while
the vasopressor sensitivity is assessed. Once the vasopressor sensitivities are assessed, then the vasopressors are ‘de-
escalated’ accordingly. We believe that this concept may offer a new approach to the treatment of septic shock.
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Background
Sepsis remains the most common cause of vasodilatory
shock worldwide. International consensus guidelines
describe specific recommendations regarding treatment.
These include the timing of important interventions
comprising blood culture collection, initiation of broad-
spectrum antibiotics, blood glucose targets, use of steroids,
and restoration of optimal hemodynamic status [1]. The
mainstay of treatment with regard to restoring and main-
taining optimal hemodynamic status is rapid and appropri-
ate fluid bolus therapy (FBT) which, if insufficient, is
followed by vasopressor therapy to maintain an acceptable
mean arterial pressure (MAP). Despite this approach being
a cornerstone of therapeutic guidelines, there is a lack of
high-quality evidence demonstrating a survival benefit
associated with the use of one vasopressor over another [2].
Although current consensus guidelines recommend nor-
epinephrine as the first-line vasopressor, both selection and
timing of second-line therapy in refractory hypotension due
to septic shock is highly variable. Indeed, in a recent survey
of practice, only 14% of respondents cited a predefined dose
of the first agent as the stimulus for additional therapy [3,
4]. Selection of the vasopressor agent is also variable and
further complicated by the recent data related to a “new”
vasopressor, angiotensin II, which is currently only available
in the USA [5, 6].
Main text
Given that all routinely used catecholamines target the
same adrenergic receptors, most clinicians are inclined
to add a non-catecholamine vasopressor to treat patients
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with refractory hypotension due to septic shock, a deci-
sion based on three key factors: availability (a relatively
rigid constraint), familiarity (often governed by previous
practice), and safety profile. In our opinion, further
consideration should be potential vasopressor response.
Following appropriate volume resuscitation, the
response to different vasopressor classes is neither
uniform nor predictable. Furthermore, the responsive-
ness to a vasopressor may impact the outcome.
Indeed, norepinephrine, recognized as the first-line
vasopressor, often demonstrates a variable response
which may be due to various factors which include
pre-existing therapy/medications, genetics, the under-
lying pathophysiology of septic shock, and/or receptor
responsiveness [7–10]. Both human and pre-clinical
data demonstrate that septic shock impairs
sympathetic modulation of the heart and vasculature
[7]. In fact, septic shock patients who maintain adren-
ergic responsiveness have better outcomes [9]. Simi-
larly, non-catecholamine vasopressors including
vasopressin and angiotensin II can be affected by con-
comitant medications, genetics, and altered receptor
responsiveness as a consequence of inflammation and
sepsis [10–12]. The net effects of all of these parame-
ters are difficult to compute at the bedside, but the
key issue is whether responsiveness to a vasopressor
impacts outcomes.
Non-responders to high-dose catecholamines have a
dismal outcome [13]. In terms of non-catecholamine
agents, less than 50% of patients demonstrate a MAP
response to low-dose vasopressin with this group hav-
ing a significantly better survival than those that fail
Table 1 Outcomes Assessed by MAP Response to Vasopressin or Angiotensin II
Vasopressin [14] Angiotensin II [6]
Responder 45%
(n = 426)
Non-responder
55% (n = 512)
P value Responder
69.9% (n = 114)
Non-responder
30.1% (n = 49)
P value
In-patient mortality (%) 56.6% 71.7% < 0.001 35% 71% < 0.0001
Catecholamine dose (mcg/kg/min) 0.35 ± 0.25 0.33 ± 0.27 0.18 0.32 ± 0.32 0.53 ± 0.39 0.0002
MAP (mmHg) 69 ± 12 65 ± 12 < 0.001 67.1 ± 5.21 64.8 ± 5.02 0.0087
Steroids (%) 58.9 62.5 0.26 55.3 57.1 0.8647
Lactate (mmol/L) 4.0 ± 3.6 5.4 ± 4.8 < 0.001 3.43 ± 2.43 5.80 ± 6.01 0.013
SOFA score 13 ± 4 12 ± 3 0.49 11.65 ± 2.78 12.06 ± 2.99 0.4313
Age, years 62 ± 14 61 ± 15 0.17 61.7 ± 15.32 63.1 ± 16.33 0.4278
Fig. 1 Survival probability by MAP response at hour 3 for patients in the ATHOS-3 trial
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to respond [14] (Table 1). Similarly, approximately
70% of patients who receive angiotensin II have a
MAP response. [6, 15] In a responder analysis, the
ATHOS-3 study showed that a responder’s chance of
survival is significantly better than that of patients
who fail to respond to angiotensin II [6, 15] (Table 1,
Fig. 1). It follows that in patients with septic shock,
the choice of vasopressor should be governed by the
patient’s likelihood of responding and the sensitivity
to treatment. This notion is in keeping with current
antimicrobial therapy paradigm wherein clinicians
obtain cultures and start broad-spectrum antibiotics
with the intention of de-escalating the antibiotics
once the causative organism is identified.
Conclusion
We propose the notion of “broad spectrum vasopressors”
wherein patients with septic shock are started on multiple
vasopressors with a different mechanism of action simultan-
eously while the vasopressor sensitivity is assessed. Vaso-
pressor sensitivity could be assessed by sequential removal
of vasopressors or developing a vasopressor sensitivity panel.
Once the vasopressor sensitivities are assessed, then the va-
sopressors are de-escalated accordingly. However, this con-
cept is hampered by several issues. Firstly, there is currently
no bedside test that predicts the blood pressure response to
catecholamines, vasopressin, or angiotensin II. Secondly, not
all of these vasopressors are currently available worldwide
due to either a lack of regulatory approval or cost consider-
ations. Thirdly, there are no prospective data supporting this
approach. Despite these hurdles, we feel that this is a test-
able hypothesis: Does time to sensitive vasopressor response
improve outcomes in septic shock? We suggest this is a
question worth answering and may prove an essential ap-
proach in managing these critically ill individuals.
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